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The majority of colorectal cancers (CRCs) arise from adenomatous polyps. In this study, we sought to present the
underrecognized CRC with the residual polyp of origin (CRC RPO+) as an entity to be utilized as a model to study
colorectal carcinogenesis. We identified all subjects with biopsy-proven CRC RPO+ that were evaluated over 10 years
at Mayo Clinic, Rochester, MN, and compared their clinical and pathologic characteristics to CRC without remnant
polyps (CRC RPO−). Overall survival and disease-free survival overlap with an equivalent hazard ratio between CRC
RPO+ and RPO− cases when age, stage, and grade are adjusted. The somatic genomic profile obtained by whole
genome sequencing and the gene expression profiles by RNA-seq for CRC RPO+ tumors were compared with that of
age -andgender-matchedCRCRPO−evaluatedbyTheCancerGenomeAtlas. CRCRPO+casesweremore commonly
foundwith lower-grade, earlier-stagedisease thanCRCRPO−. However,within the samedisease stage andgrade, their
clinical course is very similar to that of CRC RPO−. The mutation frequencies of commonly mutated genes in CRC are
similar between CRC RPO+ and RPO− cases. Likewise, gene expression patterns are indistinguishable between the
RPO+ and RPO− cases. We have confirmed that CRC RPO+ is clinically and biologically similar to CRC RPO− and
may be utilized as a model of the adenoma to carcinoma transition.
Translational Oncology (2016) 9, 280–286Introduction
In the United States, colorectal cancer (CRC) is the second leading
cause of cancer-related mortality [1]. The majority of CRCs are
presumed to arise from adenomatous polyps, which are present in atleast one third of individuals undergoing screening colonoscopy [2–5].
However, in the majority of CRC patients, no residual adenomatous
polyp tissue is detectable in the specimen obtained at the time of surgical
resection (CRC RPO−). It has not been possible, due to the ethicalontents are solely the responsibility of the authors and do not necessarily represent the
fficial view of the National Institutes of Health.
These authors have contributed equally.
eceived 8 June 2016; Accepted 13 June 2016
2016 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open
cess article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
936-5233/16c
o
3
R
©
ac
1
http://dx.doi.org/10.1016/j.tranon.2016.06.002
Translational Oncology Vol. 9, No. 4, 2016 CRC RPO+ resembles CRC in general Druliner et al. 281concerns with leaving a premalignant lesion in a patient, to study the
transition and progression of a polyp to cancer in humans, thus limiting
researchers to the use of animal models, cell lines, or comparisons of
polyps and cancers from different individuals. These studies have
contributed valuable knowledge to the field of CRC, with the caveat
that extensive extrapolation of the transformation from benign polyp to
cancer within an individual was required.However, in a small portion of
CRC cases, the residual polyp of origin (CRC RPO+) is still present
within the resected lesion. These residual polyps, adjacent to the cancer,
provide a window of opportunity to study the evolution of adenoma to
carcinoma, thus expanding our understanding of malignant transfor-
mation [6]. It is not known whether there are features unique to CRC
RPO+ that allow the polyp of origin to remain and not be completely
consumed by the tumor or if the cancer component of the CRC RPO+
cases is similar to the CRC RPO− cancer.
In other words, in order for the CRC RPO+ model to be pertinent to
the majority of CRCs in which the residual polyp of origin does not
remain, it is crucial to determine if CRC RPO+ cases have the same
characteristics—molecular, histological, or clinical—as CRCRPO− cases.
In this study, we sought to determine if there were differences in the
cancer tissue of CRC RPO+ and RPO− cases. If CRC RPO+ cases
resemble CRC RPO− cases, then CRC RPO+ cases can serve as a valid
model for future studies investigating the transition from the
premalignant to malignant CRC state.
Material and Methods
Sample Characteristics and Annotation
Demographics and clinical outcome data were reviewed and
abstracted from the electronic medical record for all patients with
CRC who had surgical resection at Mayo Clinic, Rochester, MN, from
2004 to 2015 and who had given authorization for research. This study
was approved by our institutional review board. Patients with
biopsy-proven CRC were classified into CRC RPO+ and CRC
RPO−. CRCRPO+ are those cases with residual polyp contiguouswith
their primary cancer present on pathologic review of histologic slides
from the surgical specimen, and CRC RPO− are those cases in which
no residual polyp tissue was found in association with the tumor.
Mismatch repair status (MMR) was determined by review of
immunohistochemistry studies for MMR proteins. MMR deficiency
(d-MMR) was defined as lack of staining for the MMR proteins
MLH1, MSH2, MSH6, and/or PMS2. Proficient MMR was defined
as presence of staining for all four of these proteins. The frequency of
d-MMR and p-MMR was compared between these two groups.
Tissue Preparation and DNA Extraction
We utilized a total of 10 CRC RPO+ cases for molecular study.
Tumor specimens were harvested following surgical resection and snap
frozen in liquid nitrogen. Up to three 1-cm2 full-thickness specimens
from the center and edge of the cancer were collected. In addition to
cancer tissues, three 1-cm2 normal colonic epithelium full-thickness
specimens at least 8 cm from the polyp/tumor margin were harvested.
Regions were identified by an expert gastrointestinal pathologist
(T.J.S.) on a hematoxylin and eosin (H&E)–stained 4-μm–thick
section of the frozen tissue blocks collected from surgical specimens
from consented participants of the Biobank for Gastrointestinal
Health Research (IRB 622-00, PI L.A. Boardman). Tumor tissue was
macrodissected to enrich for tumor density (N70%). All CRC RPO+
tissues used here excluded subjects with a prior history of any
malignancy, a family history of Lynch syndrome or familialadenomatous polyposis, and any other syndrome associated with
hereditary CRC or inflammatory bowel disease. DNA was manually
extracted utilizing PureGene chemistry (Gentra Systems, Minneapolis,
MN). RNA was extracted using Qiagen MiRNeasy mini kit.
Whole Genome Sequencing of 10 CRC RPO+ Cases
For library construction, total DNAwas quantified in triplicate using
the Quant-iT PicoGreen DNA Assay Kit and normalized to 2-ng/μl
minimum concentration. An aliquot of 100 ng for each sample was
transferred into library preparation utilizing the Broad Institute–
developed one-well protocol. All biochemistry occurs in a single well
without the need for sample transfer (the sample is reversibly
immobilized to and released from magnetic beads, allowing washes
and reagent addition). The one-well protocol streamlines the process
and greatly reduces sample input requirements. The product provides
one library (typical median insert size of library is 330 bp) [7].
Samples were sequenced on the Illumina HiSeq X instruments
producing 150-bp, paired-end reads to meet a goal of 30× mean
coverage. Using the Picard Informatics Pipeline, all data from a
particular sample were aggregated into a single Binary Alignment/Map
format (BAM) file which included all reads, all bases from all reads, and
original/vendor-assigned quality scores. A pooled Variant Call Format
file using the latest version of Picard GATK software was generated
and provided for each sample batch. All whole genome sequencing
data analyzed in this manuscript will be uploaded to SRA through
dbGaP (Accession numbers to follow).
Mutation Frequency Detection. In order to detect somatic single
nucleotide variants (SNVs) between the tumor and matched normal
tissue SNVs for 10 cases of CRC RPO+, we used 4 different somatic
variant callers: MuTect, SomaticSniper, Strelka, and VarScan [8–11].
Those callers were run with default options for normal and tumor
samples from each patient. We took common SNVs detected by at
least two different callers. Variant allele frequencies for those SNVs
were calculated from sample BAM files for each patient using an
in-house script. To annotate them, we used Variant Effect Predictor
(http://www.ensembl.org/Tools/VEP).
Tumor somatic mutation profiles for CRC RPO− were obtained
from The Cancer Genome Atlas (TCGA) for 32 pMMRCRCs which
were stage, site, gender, and age matched to the 10 pMMR CRC
RPO+ cases described above. The somatic mutation profiles were
downloaded in Mutation Annotation Format, which classifies
somatic mutations into 1 of 13 categories depending on the type
and sequence position of the corresponding mutation. SNVs that
caused frame shift in/del, in frame in/del, missense mutation, or
nonsense mutation, or involved a splice site were classified as being
likely to impact a gene’s function. A gene was considered as mutated
when it had at least one somatic mutation in at least one of these
categories [12]. The frequency of somatic mutation rates from the
WGS studies on the cases of CRC RPO+ were compared with the
mutation profiles reported for the matched TCGA cases presumed to
be mainly CRC RPO−.
RNA Sequencing of 16 CRC RPO+ Cases
Total RNA was quantified using the Quant-iT RiboGreen RNA
Assay Kit and normalized to 5 ng/μl. An aliquot of 200 ng for each
sample was transferred into library preparation which was an automated
variant of the Illumina TruSeq Stranded mRNA Sample Preparation
Kit. This method preserves strand orientation of the RNA transcript.
Oligo dT beads were used to select mRNA from the total RNA sample.
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followed. The resultant cDNA went through library preparation (end
repair, base “A” addition, adapter ligation, and enrichment) using
Broad-designed indexed adapters substituted in for multiplexing. After
enrichment, the libraries were quantified with quantitative polymerase
chain reaction using the KAPA Library Quantification Kit for Illumina
Sequencing Platforms and then pooled equimolarly. The entire process
is in 96-well format, and all pipetting is done by either Agilent Bravo or
Hamilton Starlet.
Pooled libraries were normalized to 2 nM and denatured using 0.1 N
NaOH prior to sequencing. Flowcell cluster amplification and
sequencing were performed according to the manufacturer’s protocols
using either the HiSeq 2000 or HiSeq 2500. Each run was a 101-bp
paired-end with an 8-base index barcode read. Data were analyzed
using the Broad Picard Pipeline which includes demultiplexing and
data aggregation.
Processing of RNA-Seq Data and Comparison to TCGA CRC
The paired-end RNASeq FASTQ files were then analyzed usingMayo
Clinic’s standard RNA-Seq application, MAPR-Seq v.2.0.0 (http://
bioinformaticstools.mayo.edu/research/maprseq/). MAPR-RSeq inte-
grates a suite of open-source bioinformatics tools along with in-house–
developedmethods to analyze paired-endRNA-Seq data. Read alignment
was performed with Tophat [13] which uses Bowtie [14]—a fast,
memory-efficient, short-sequence aligner. The reads were aligned to the
transcriptome (Ensembl GTF) and to the genome (hg19) to report both
existing and novel expressed regions. The BAM file produced by Tophat
was processed using featureCounts [15] to summarize expression at the
gene and exon levels. Reads per kilo base per million (RPKM) values were
calculated from the raw gene counts produced by featureCounts and by
incorporating the total number of aligned reads and the coding length of
each gene. To identify possible quality control issues, RSeQC software
[16] was used to detect abnormalities, such as unsymmetrical gene body
coverage, high levels of read duplication, and low saturation levels of
known exon junctions, within each sample.
The TCGA colorectal adenocarcinoma and rectal adenocarcinoma
RNASeq expression data were obtained from the following site, https://
tcga-data.nci.nih.gov/docs/publications/coadread_2012/, and their anno-
tation file was obtained from https://tcga-data.nci.nih.gov/tcgafiles/
ftp_auth/distro_ftpusers/anonymous/other/GAF/GAF_bundle/outputs/
TCGA.Sept2010.09202010.gaf. RPKM values are directly impacted
by gene length, so only the genes with a similar length between the
TCGA annotation file and the Mayo Clinic annotation file (ftp://ftp.
ensembl.org/pub/grch37/update/gtf/homo_sapiens/Homo_sapiens.
GRCh37.82.gtf.gz) were used within this analysis. Specifically, genes that
had a gene length within 10% of each other from both references were
kept. For these similar genes identified, the RPKM values were extracted
from the TCGA analyzed expression data and from the Mayo analyzed
expression data. Note, the bioinformatics tools used to align and calculate
expression from the TCGA analyzed samples were different from those
used for theMayo analyzed samples. All the genes that had no expression
from the TCGA analyzed or the Mayo analyzed samples were removed.
Mean and standard deviation values were calculated from the RPKM
values across theTCGAanalyzed group and for theMayo analyzed group.
The genes that had a standard deviation greater than the mean were also
removed from this analysis to avoid evaluating highly variable genes, such
as circadian rhythm genes. The sample specific RPKM values from the
Mayo analyzed samples and the TCGA colorectal adenocarcinoma and
rectal adenocarcinoma samples with similar clinical characteristics werethen extracted and visualized within a heatmap. The heatmap was
constructed using the Complex Heatmap function in R through the
Bioconductor package [17]. All RNA-seq data analyzed in this
manuscript will be uploaded to SRA through dbGaP (accession numbers
to follow).
Statistical Analyses
Student’s t test was used to determine statistical significance of
continuous variables, and χ2 test was used for categorical variables.
Univariate and multivariate analyses were conducted to adjust for
potential confounders. Overall survival (OS) and disease-free survival
(DFS) were defined as the time in months from the diagnosis to death
from any cause and time from the date of diagnosis to the date of
recurrence or death, respectively. Survival outcomes were reported as
the hazard ratio (HR) calculated in the Cox regression model and
presented by Kaplan-Meier curves comparing the observed and
predicted events after adjustment for sex, stage, and grade in the Cox
model. A P value less than .05 was considered to be significant.
Correlations were determined using Spearman’s rank correlation. All
the statistical analyses were performed using the SAS JMP or R software.
Results
CRC with residual polyp of origin as a model of malignant
transformation
In this study, we sought to examine possible biological and clinical
differences between colorectal tumors with and without the residual
polyp of origin present. Because CRC with the polyp of origin
remaining (CRCRPO+) is an underrecognized event, it was our goal to
determine if these cases are representative of the majority of CRCs in
which there is no residual polyp present (CRC RPO−) at the time of
diagnosis or surgery and thereforemay be a soundmodel for the study of
colorectal carcinogenesis (Figure 1A). To determine whether this model
is truly representative of CRC irrespective of the presence of the
precursor lesion, we have studied CRC RPO+ tumors in terms of
clinical course, histologic features, and genetic profiles and compared
them with CRC RPO− tumors.
Baseline demographics and histological characteristics of CRC
RPO+ and RPO−
From those cases identified as having undergone surgery at
Mayo Clinic Rochester between 2004 till 2015, a total of 543
patients with CRC RPO+ and 4101 patients with CRC RPO− were
included in the study. We found that baseline demographics
including age and sex distribution were similar in both groups
(Table 1). Among those RPO+ cases, 332 (61%) of the cases were
found to have tubulovillous lesions, 29 (5%) villous, and 182 (34%)
adenomatous not otherwise specified.
CRC RPO+ cases were more likely to be low-grade (moderately or
well-differentiated) lesions (56.6% low vs 43.4% high grade) compared
with RPO− lesions which were more likely to be high grade (poorly or
undifferentiated) tumors (32.2% low vs 67.8% low grade), P b .0001
(Table 1). Immunohistochemistry studies for MMR proteins on 70
specimens of CRC RPO+ were compared with 621 CRC RPO− cases.
Fifteen (21.4%) of the CRC RPO+ group and 125 (20.1%) of the
RPO− group had deficient mismatch repair with absence of expression
of MLH1, MSH2, MSH6, and/or PMS2, P = .79. Upon pathologist
review of hemotoxylin and eosin–stained sections of CRC RPO+ and
CRC RPO− cases, there were no qualitative distinctions overall
between the tumors (Figure 1B).
Figure 1. Amodel ofmalignant transformation: CRCwith residual polyp of origin. (A) CRCwith the residual polyp of origin (CRCRPO+) is represented
schematically here andbyH&E straining. The anatomical location in the colon of the polyp and cancer in the diagramserves only as an exemplar case as
tumor locationhasno impacton the likelihoodof findingaCRCRPO+case.TheH&Estain isacross-sectionof the residual polypoforiginadjacent to the
cancer tissue. (B)H&E tissuesections fromthreeCRCRPO+cases (left) and fiveCRCRPO−cases (right). For theCRCRPO+cases, thecancer tissue is
shown in red brackets, and the polyp tissue is shown in black brackets. All cases are poorly differentiated tumors, and the cases are also matched by
stage.Anadditionalschematic isshownto illustratea typicalCRCRPO−case,where thecancer is foundatadistant location to thepresenceof thepolyp.
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RPO−
The average tumor size reported by Surveillance, Epidemiology,
and End Results statistics was significantly larger (47.3 mm) in CRC
RPO− cases compared with that in RPO+ cases (35.3 mm), P b .0001.
There was no significant difference in the distribution of the anatomical
location of the tumor between the two groups. The majority (65%) of
CRC RPO+ cases were stage 1 compared with 20.6% of the CRC
RPO− cases, P b .0001. CRC RPO− cases were diagnosed at a higher
stage than RPO+ cases (25.0%CRCRPO− vs 12.3%CRC RPO+ for
stage II, 28.7% vs 13.6% for stage III, and 25.6% vs 9.0% for stage IV
cancers, respectively, P b .0001 across all stages).
Over 11 years of follow-up, there were a total of 1528 (33%) deaths
within the 2 groups combined, out of which 116 (21%) events occurredamong CRC RPO+ patients and 1412 (38%) among CRC RPO−
patients. CRC RPO+ cases have similar OS and DFS performance as
CRC RPO− cases after adjustment for age, sex, stage, and grade
(OSHR = 1.18, 95% confidence interval [CI] 0.96-1.44, P = .11; DFS
HR = 1.12, 95%CI 0.91-1.38, P = .27). The predicted OS (Figure 2A)
and DFS (Figure 2B) curves after adjusting for sex, stage, and grade
overlapped between the two groups.
Genomic analysis of CRC RPO+ and RPO−
The Cancer Genome Atlas Network published a report in 2012 that
identified 17 somatic recurrently mutated genes in nonhypermutated
(pMMR) CRC [12]. Among those 17 genes and in the nonhypermutated
cancers, the 8 most frequently mutated genes were APC, TP53, KRAS,
PIK3CA, FBXW7, SMAD4, TCF7L2, and NRAS. We compared the
Table 1. Sample Characteristics.
Parameter CRC RPO+ (%) CRC RPO− (%) P Value
Number of Patients 543 (11.7) 4101 (88.3)
Age .82
Mean (SD) 64.6 65.7
Median 66 67
SD 13.6 14.3
Range (16-98) (19-97)
Gender .15
Female 216 (39.8) 1762 (43)
Male 327 (60.2) 2339 (57)
Tumor Location .17
Right colon 206 (37.9) 1610 (39.3)
Left colon 129 (23.8) 1033 (25.2)
Rectosigmoid 198 (36.5) 1338 (32.6)
Not specified 10 (1.8) 120 (2.9)
Tumor Stage b .0001
I 353 (65.0) 845 (20.6)
II 67 (12.3) 1026 (25.0)
III 74 (13.6) 1177 (28.7)
IV 49 (9.0) 1053 (25.7)
Number of examined lymph nodes .0001
Mean (SD) 18.2 21.0
Median 16 19
SD 0.7 0.2
Range (0-90) (0-90)
Number of positive lymph nodes b .0001
Mean (SD) 0.7 1.8
Median 0 0
SD 0.17 0.06
Range (0-19) (0-48)
Grade b .0001
Well differentiated 25 (4.6) 108 (2.6)
Moderate differentiated 262 (48.2) 1136 (27.7)
Poor differentiated 218 (40.2) 237 (57.7)
Undifferentiated 2 (0.4) 259 (6.3)
Unknown 36 (6.6) 233 (5.7)
Tumor Size (EOD) b .0001
Mean (SD) 35.3 47.2
Median 16.25 42
SD 1.6 0.5
Range (1-198) (1-600)
MMR Status .79
pMMR 55 (78.6) 496 (79.9)
dMMR 15 (20.3) 125 (20.1)
Figure 2. Survival analysis between CRC RPO+ and RPO− tumors. K
and CRC RPO−. Solid lines are representative of unadjusted observ
after adjustment for disease stage and grade.
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CRC RPO+ and 33 tumor samples matched for age, gender, and stage
downloaded from the TCGA. The most commonly mutated genes in our
sample set of CRC RPO+ were APC, TP53, and KRAS, which were
mutated in 6 of the 10 cases (60%).When comparedwith theTCGAdata,
the expected frequency ofmutated genes in ourCRCRPO+casesmirrored
the mutation profile of those TCGA CRC cases that likely did not have
RPO (Figure 3A). The mutations included missense and inactivating
variants. The TCGA reported that ACVR2A, APC, TGFBR2, MSH3,
MSH6, SLC9A9, and TCF7L2 were frequently mutated in the
hypermutated tumors, so we obtained sequencing data on an additional
two hypermutated (dMMR) CRC RPO+ cases. When we compared the
mutation frequencies of genes identified by the TCGA as commonly
mutated in hypermutated CRC tumors, we found that the majority of
those genes were also mutated in our two CRC RPO+ dMMR tumors.
Gene expression analysis of CRC RPO+ and RPO−
We also compared gene expression patterns between CRC RPO+
cases that were subjected to RNA-seq with data from TCGA CRC
tumors, matched by site, stage, gender, and age [12]. Expression values
(RPKM) were plotted in a heatmap for 16 CRC RPO+ cases and 32
tumor samples from the TCGA (Figure 3B). Overall, there are virtually
no differences between the CRC RPO+ and TCGA groups (r = 0.88,
P b 2.2e-16). TCGA samples cluster with the RPO+ samples, and there
are minor clusters even within a major branch of the TCGA group. It is
important to note that any differences seen may be attributed to
differences in sample prep, sequencing technology, and bioinformatics
between the CRC RPO+ and TCGA cases.
Discussion
Adenomatous polyps are the presumed precursor lesion of CRC, and
reports on the decline in CRC incidence from large population-based
epidemiologic studies being attributable to the increased frequency of
colonoscopy and subsequent polypectomy support that polyps are likely
to be the precursors to CRC [18,19]. The multistep model of colorectal
carcinogenesis has been identified by combining molecular data on
polyps and CRCs from different individuals. This is due to the fact that
the polyp fromwhich the cancer was presumably derived often does notaplan-Meier curves comparing (A) OS and (B) DFS for CRC RPO+
ations, and dashed lines are representative of predicted outcomes
Figure 3. Mutation frequency and gene expression signatures are
comparable between CRC RPO+ and RPO− tumors. (A) Somatic
mutation frequency of 11 genes found to be commonly mutated in
CRC.We compared the mutation frequencies of these genes from 10
CRC RPO+ cases and 32 CRC RPO− cases from the TCGA. TCGA
sampleswerematched by age and stage to our 10 CRCRPO+cases.
These mutation frequencies were not significantly different between
CRC RPO+ and RPO− cases. (B) CRC RPO+ and TCGA CRC tumors
are virtually indistinguishable fromeachotheron thebasis of their gene
expression patterns. Plotted in this heatmap are the RPKM values for
expression of genes following RNA-seq. Hierarchical clustering with
k=5was performed for genes and both CRCRPO+and TCGA tumor
cases. The left axis is the clustering for the CRC RPO+ and TCGA
tumors, and the top axis is the clustering for the genes. For the case
clustering, each cluster is colored for clarity. Red represents genes
with highest expression, and blue is the lowest.
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from a surgical cancer specimen may be absent in the pathology report
because the cancer diagnosis has the more significant impact on the
clinical care for the patient. We propose CRC RPO+ as a model inwhich to study malignant transformation, but the features of the cancer
with polyp remaining have not been well characterized. Through our
examination of clinical behavior, histologic, genetic, and transcriptional
features, we have shown the CRC RPO+ cancers are indistinguishable
from CRC RPO−. Based on these results, studies that examine the
adenoma to carcinoma transition can directly compare CRC tumor
tissues, regardless of RPO status.
We have found that CRCRPO+ cases are more likely to be smaller in
size and earlier stage than their RPO− counterparts. It is important to
note that the stage-adjusted survival outcomes of these patients are
almost identical to those with CRC RPO−. This observation can be
explained by the fact that, over time, as the tumor grows andmetastasizes
to regional and distant locations, it will outgrow and consume the polyp
of the origin, making it less likely to be detected when diagnosed at the
higher stage. This theory is supported by the fact that RPO− tumors tend
to be larger in size when compared with RPO+ ones.
We discovered that CRCs RPO− more commonly present as
poorly differentiated tumors. This observation suggests that
high-grade tumors grow faster and are more likely to obliterate the
precursor lesion before resection. The other possibility would be that
CRCs RPO− follow a different pathway in the process of cancer
development that does not require origination from a premalignant
neoplasm. Although CRCs RPO− tend to present as a high-grade
lesion, there is no tendency for deficient MMR status in either group.
CRC RPO+ resembles CRC in general regardless of RPO status
in terms of somatic mutation frequency rate of genes reported as
commonly altered in colorectal carcinogenesis. Given the relatively
small sample size in our cohort of 10 CRC RPO+ patients who
underwent whole genome sequencing, our study could be
underpowered to pick up small differences in the frequency of the
mutated genes between the two groups, but given the similarity
between the groups, this is not likely. It is feasible that some of the
TCGA CRC cases were RPO+, but the odds that they represented
the majority of these subjects are quite low, as frequency of these
types of cases is approximately 10% as shown in this study. It is also
possible that the frequency of RPO+ lesions is underestimated
secondary to the histologic undercalling, as pathologists may not
report coexistence of the premalignant polyp with cancer. Although
less likely, the frequency of the polyp as the lesion of origin for CRC
potentially can be also overestimated if the polyp and the cancer both
arise independently from the same anatomical location.
CRC RPO+ is an entity that has the potential to be utilized as a
unique model representative of the mutagenic path of malignant
transformation. This model is reminiscent of dysplastic nevi in a
malignant melanoma lesion, which has been presented as an ideal
model for studying nevus transformation to nevus-derived melano-
mas [20,21]. Through our careful collection of CRC RPO+ cases, we
have shown that they are indistinguishable from CRC RPO−, and
based on that result, we conclude that CRC regardless of RPO status
can be compared directly in future studies.
Conclusions
Overall, in this study, we have shown that cancer tissues of CRC
RPO+ cases are clinically and biologically similar to the CRC
RPO− cases despite the tendency to be more commonly detected
at an earlier disease stage and lower grade. This model provides
the opportunity for future studies to discover the underlying
mechanisms involved in the carcinogenesis through interrogation
of genetic, transcriptional, and epigenetic events in this process.
286 CRC RPO+ resembles CRC in general Druliner et al. Translational Oncology Vol. 9, No. 4, 2016This study also confirms for existing studies that the cancer component
of CRC RPO+ cases is not a unique malignancy and is comparable to
CRC in general. Because CRC RPO+ recapitulates the clinical and
biological profile of CRC RPO−, we propose that CRC RPO+ will
provide the opportunity to advance the understanding of neoplastic
transformation mechanisms and will result in better recognition of
high-risk precursor lesions leading ultimately to developing preventative
measures and targeted therapies.
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